Your browser is no longer supported. Please, upgrade your browser.
Settings
MNKD MannKind Corporation daily Stock Chart
MNKD [NASD]
MannKind Corporation
Index- P/E0.99 EPS (ttm)1.38 Insider Own- Shs Outstand104.14M Perf Week3.03%
Market Cap141.63M Forward P/E- EPS next Y-0.80 Insider Trans- Shs Float82.15M Perf Month-11.11%
Income134.20M PEG0.04 EPS next Q-0.24 Inst Own23.30% Short Float27.80% Perf Quarter27.10%
Sales177.80M P/S0.80 EPS this Y130.10% Inst Trans27.42% Short Ratio6.14 Perf Half Y-58.15%
Book/sh-2.08 P/B- EPS next Y8.00% ROA125.50% Target Price- Perf Year-72.43%
Cash/sh0.46 P/C2.95 EPS next 5Y26.80% ROE-54.40% 52W Range0.67 - 5.10 Perf YTD-57.28%
Dividend- P/FCF- EPS past 5Y17.20% ROI-396.80% 52W High-73.33% Beta3.30
Dividend %- Quick Ratio0.60 Sales past 5Y411.30% Gross Margin87.40% 52W Low104.14% ATR0.11
Employees153 Current Ratio0.60 Sales Q/Q- Oper. Margin78.60% RSI (14)50.34 Volatility8.36% 8.57%
OptionableYes Debt/Eq- EPS Q/Q41.20% Profit Margin75.50% Rel Volume0.23 Prev Close1.38
ShortableYes LT Debt/Eq- EarningsAug 09 AMC Payout0.00% Avg Volume3.72M Price1.36
Recom4.00 SMA20-0.22% SMA50-2.14% SMA200-38.34% Volume1,014,767 Change-1.45%
May-10-16Reiterated RBC Capital Mkts Underperform $0.15 → $0.20
May-10-16Reiterated Piper Jaffray Underweight $0.05 → $0.10
Jan-06-16Reiterated RBC Capital Mkts Underperform $1 → $0.15
Jan-06-16Reiterated Piper Jaffray Underweight $1.50 → $0.05
Nov-04-15Downgrade RBC Capital Mkts Outperform → Underperform $9 → $1
Sep-09-15Downgrade Piper Jaffray Neutral → Underweight
Aug-03-15Reiterated RBC Capital Mkts Outperform $10 → $9
May-11-15Reiterated MLV & Co Hold $7 → $4
May-11-15Downgrade JP Morgan Neutral → Underweight
Apr-16-15Reiterated RBC Capital Mkts Outperform $13 → $10
Aug-12-14Reiterated RBC Capital Mkts Outperform $16 → $13
Jul-01-14Downgrade MLV & Co Buy → Hold $11
Jun-30-14Reiterated Brinson Patrick Market Outperform $12 → $15
Jun-13-14Initiated RBC Capital Mkts Outperform $16
Apr-02-14Reiterated MLV & Co Buy $9 → $11
Jun-27-13Reiterated MLV & Co Buy $6 → $8
May-15-13Initiated MLV & Co Buy $6
Apr-13-12Initiated Cowen & Co Neutral
Feb-23-12Reiterated JMP Securities Mkt Outperform $7 → $5
Aug-12-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $7
Jul-17-17 09:00AM  Steven Binder Joins MannKind as Chief Financial Officer GlobeNewswire +5.47%
Jul-14-17 08:20AM  Today's Research Reports on Stocks to Watch: Mannkind Corporation and AstraZeneca Accesswire
Jul-13-17 08:51AM  Options Traders Expect Huge Moves in MannKind (MNKD) Stock Zacks +12.82%
Jul-12-17 09:00AM  Patrick McCauley Joins MannKind as Chief Commercial Officer GlobeNewswire
Jun-29-17 09:26AM  MannKind Renegotiates Near-Term Maturities with Deerfield GlobeNewswire -6.45%
09:00AM  MannKind Draws Remaining Funds under Mann Group Loan Arrangement GlobeNewswire
Jun-28-17 09:00AM  MannKind Draws Remaining Funds under Mann Group Loan Arrangement GlobeNewswire
Jun-16-17 08:47AM  Is the Options Market Predicting a Spike in MannKind (MNKD) Stock? Zacks
Jun-09-17 08:24AM  3 Surging Penny Stocks You'll Want Nothing to Do With Motley Fool
Jun-05-17 09:00AM  MannKind Engages Locust Walk to Explore Strategic Options for MannKinds Non-insulin Technosphere-based Pipeline Candidates GlobeNewswire
May-31-17 06:00PM  MannKind and Biomm Enter Into Distribution Agreement for Afrezza in Brazil GlobeNewswire -7.88%
May-30-17 09:00AM  MannKind Provides Update on Senior Management GlobeNewswire +8.55%
08:35AM  MannKind Corporation (MNKD) Catches Eye: Stock Jumps 7% Zacks
May-25-17 09:50AM  Short Sellers Raise the Stakes in Major Biotechs 24/7 Wall St. +10.94%
May-17-17 03:08AM  Edited Transcript of MNKD earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents -9.84%
May-11-17 08:41PM  Edited Transcript of MNKD earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents -20.31%
04:09PM  Here's Why MannKind Corporation Stock Is Tanking Today Motley Fool
08:46AM  Implied Volatility Surging for MannKind Corporation (MNKD) Stock Options Zacks
08:00AM  Today's Research Reports on Stocks to Watch: MannKind and Neuralstem Accesswire
May-10-17 04:27PM  MannKind reports 1Q loss Associated Press +42.86%
04:05PM  MannKind Corporation Reports 2017 First Quarter Financial Results GlobeNewswire
10:30AM  Investor Network: MannKind Corporation to Host Earnings Call Accesswire
May-09-17 08:00AM  Today's on Research Reports on Biotech Stocks to Watch: TherapeuticsMD and MannKind Accesswire +10.89%
May-08-17 01:40PM  MannKind Jumps After Amazon Prime Takes on One Drop 24/7 Wall St. +26.69%
May-04-17 08:00AM  MannKind and One Drop to collaborate on delivering better health outcomes for people with diabetes GlobeNewswire
Apr-28-17 09:00AM  MannKind Corporation to Hold 2017 First Quarter Financial Results Conference Call on May 10, 2017 GlobeNewswire
Apr-20-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Soligenix and MannKind Accesswire
Apr-10-17 04:22PM  Is MannKind Corporation Getting Ready to Sell? Motley Fool -5.26%
Apr-06-17 08:09AM  Sometimes Your Smartest Investing Move Is to Remain on the Sidelines Motley Fool
Apr-03-17 09:30AM  Conatus Pharmaceuticals and MannKind Look Forward to Promoting Their Brand Accesswire -6.76%
Mar-31-17 08:05AM  3 Companies That Might Not Live to See 2020 Motley Fool
Mar-27-17 10:30AM  Short Interest Pulls Back in Major Biotechs
Mar-23-17 01:04PM  MANNKIND CORP Financials
Mar-22-17 09:23AM  Billionaires' Worst Healthcare Stock Picks for 2017 (So Far) Motley Fool
Mar-21-17 04:23PM  Could MannKind Corporation's Marketing Blitz Pay Off? Motley Fool -5.91%
Mar-20-17 09:50AM  Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now 24/7 Wall St.
Mar-17-17 04:34PM  MANNKIND CORP Files SEC form 8-K, Other Events +7.25%
02:44PM  Edited Transcript of MNKD earnings conference call or presentation 16-Mar-17 9:00pm GMT Thomson Reuters StreetEvents
Mar-16-17 04:38PM  MannKind posts 4Q profit Associated Press
04:17PM  MANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  MannKind Corporation Reports 2016 Fourth Quarter and Full Year Financial Results GlobeNewswire
09:30AM  When Profit Makers Can Be Active Profit Takers Accesswire
07:07AM  Q4 2016 MannKind Corp Earnings Release - Before Market Open
Mar-14-17 12:04PM  Top 10 Long/Short Estimize Signal Scores [Week 3/13]
Mar-13-17 12:12PM  3 Companies That Probably Won't Survive Till 2019 at Motley Fool
Mar-10-17 10:30AM  Major Biotechs See a Retreat in Short Interest
06:15AM  The 6 Most Shorted Nasdaq Stocks
Mar-09-17 10:06AM  Better Buy: MannKind Corp. vs. Dexcom at Motley Fool
Mar-08-17 09:00AM  MannKind Corporation and Charles Mattocks Announce REVERSED-Americas First Docu-Series Tackling Diabetes GlobeNewswire
Mar-07-17 12:27PM  Here's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February at Motley Fool
09:00AM  MannKind Corporation Announces Upcoming Events GlobeNewswire
Mar-06-17 09:54AM  Two Biotechs To Watch This Week: Novan Inc (NOVN) And MannKind Corporation (MNKD) at Insider Monkey -11.06%
Mar-03-17 11:39AM  Why MannKind Corporation Stock Is Sinking Today at Motley Fool -12.78%
Mar-02-17 08:02AM  MANNKIND CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matt -8.37%
Feb-28-17 11:03AM  3 Stocks to Avoid in Biotech at Motley Fool
10:15AM  Short Sellers Hike Their Bets in Major Biotechs
06:20AM  The 6 Most Shorted Nasdaq Stocks
Feb-27-17 01:58PM  Can MannKind Be Saved? at Barrons.com
Feb-23-17 04:55PM  MANNKIND CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets
Feb-21-17 09:00AM  MannKind Receives $16.7 Million From Sale of Valencia Property GlobeNewswire
Feb-10-17 09:55AM  Major Biotechs Scare Off Loads of Short Sellers
06:35AM  The 6 Most Shorted Nasdaq Stocks
Feb-07-17 10:16AM  Here's Why MannKind Corporation Rose 11.5% in January at Motley Fool -5.14%
Feb-03-17 08:46AM  Good News and Bad News for MannKind Corporation at Motley Fool
Feb-02-17 02:59PM  MannKind Looks to Boost Flagging Afrezza Sales at Investopedia -17.14%
01:08PM  Mannkind in Free Fall After Changes to Insulin Product, Sales Force
Feb-01-17 09:30AM  Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on MannKind and Keryx Accesswire
09:00AM  MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza® Growth GlobeNewswire
Jan-27-17 09:00AM  MannKind Corporation to Hold Investor Conference Call on February 1, 2017 GlobeNewswire
Jan-26-17 10:35AM  Short Sellers Back Off Major Biotechs
06:25AM  The 6 Most Shorted Nasdaq Stocks
Jan-23-17 09:01AM  Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open +8.13%
Jan-18-17 03:56PM  MannKind Has a New Plan, but Will It Work? at Motley Fool
Jan-12-17 04:00PM  Insulin Drug Offers Hope for MannKind
09:35AM  Biotech Short Sellers Run for Cover
08:02AM  MANNKIND CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
06:35AM  The 6 Most Shorted Nasdaq Stocks
Jan-10-17 04:50PM  MANNKIND CORP Files SEC form 8-K, Other Events
Jan-09-17 12:08PM  Is MannKind Corp. Ready to Rebound in 2017? at Motley Fool -5.57%
09:00AM  MannKind Receives $30.6 Million From Sanofi GlobeNewswire
Jan-05-17 10:27AM  CORRECTING AND REPLACING -- MannKind Corporation to Present at the J.P. Morgan 2017 Healthcare Conference GlobeNewswire
09:00AM  MannKind Corporation to Present at the J.P. Morgan 2017 Healthcare Conference GlobeNewswire
Jan-04-17 09:00AM  MannKind Announces Key Addition to Its Executive Management Ranks GlobeNewswire +7.41%
Jan-03-17 09:00AM  MannKind Receives $1 Million Milestone From RLS GlobeNewswire
Dec-29-16 10:08AM  Galena Biopharma Reveals Regulatory Pathway for GALE-401
09:30AM  Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, Sabre and Avinger
04:44AM  MannKind (MNKD) Shares March Higher, Can It Continue?
Dec-28-16 10:10AM  Biotech Short Interest Sinks
06:25AM  The 6 Most Shorted Nasdaq Stocks at 24/7 Wall St.
Dec-27-16 01:42PM  Nate Pile's Top Recommendations For 2017 at Forbes
Dec-22-16 02:54PM  2016 Was a Terrible Year for Biotech but the Tweets Were on Point at TheStreet
08:03AM  Alexion Soliris Fails in Phase II/III Delayed Graft Function Study
Dec-21-16 08:42AM  Celgene (CELG) Otezla Approved in Japan for Two Indications -9.37%
Dec-20-16 09:15AM  Latest Reports on Biotech Movers MannKind and Celldex Therapeutics Accesswire
Dec-19-16 08:42AM  Why MannKind (MNKD) Might Be a Diamond in the Rough +27.66%
Dec-18-16 07:35AM  Tax-Loss Selling: 3 Stocks to Dump Right Now at Motley Fool
Dec-15-16 10:06AM  Is MannKind Corporation (MNKD) a Good Stock to Buy? at Insider Monkey
06:27AM  athenahealth (ATHN) Reaffirms 2016 View, Guides for 2017
Dec-14-16 09:17AM  Envision Healthcare Acquires Desert Mountain Consultants
07:39AM  Proteon Slips to 52-Week Low on Kidney Disease Study Data
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is headquartered in Valencia, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PFEFFER MATTHEW JCEO, CFO, DirectorJan 03Buy0.544,5402,452403,085Jan 04 01:21 PM
Alinaya Rosabel RealicaSVP, Prin Acctg OfficerJan 03Buy0.549,0434,883140,456Jan 04 01:20 PM
Castagna MichaelChief Commercial OfficerAug 26Buy0.7817,50013,650212,500Aug 29 08:53 AM
Castagna MichaelChief Commercial OfficerAug 24Buy0.8715,00013,050195,000Aug 24 06:43 PM
Castagna MichaelChief Commercial OfficerAug 23Buy0.9425,00023,468180,000Aug 24 08:41 AM
PFEFFER MATTHEW JCEO, CFO, DirectorAug 15Buy0.9925,00024,650397,996Aug 16 07:54 AM
Castagna MichaelChief Commercial OfficerAug 12Buy1.0025,00024,88875,000Aug 16 07:56 AM